Enzyme immunoassay for the quantitative determination of omalizumab (Xolair®) in serum and plasma.
This kit has been especially developed for the quantitative determination of omalizumabin serum and plasma samples between the Cmin and Cmax range of concentrations.
Omalizumab Drug Bank Accession Number is DB00043
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) which treats the symptoms of asthma and chronic idiopathic urticaria by limiting the allergic response. It inhibits the binding of IgE to receptors on mast cells and basophils, blocking the IgE-mediated secretion of inflammatory mediators from these cells. Mast cell activation and the release of mediators, in response to allergen exposure and IgE, results in a cascade of events. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
